Abstract
Our understanding of human diseases caused by mutated mitochondrial DNA (mtDNA) has recently evolved dramatically. This is a group of untreatable disorders affecting the eye, nervous system, and heart, some clinically characterized more than a century ago,1 but they are now known to be a spectrum of molecularly defined diseases. In approximately 95% of the cases worldwide, Leber hereditary optic neuropathy (LHON) is caused by 3 pathogenic point mutations in mtDNA coding for the respiratory chain subunits of the nicotinamide adenine dinucleotide ubiquinone-oxidoreductase (complex I) genes: 3460G>A in ND1, 11778G>A in ND4, and 14484T>C in ND6.2 Of these 3 mutations, the 11778G>A resulting in an arginine to histidine substitution at amino acid 340 is responsible for half of the LHON cases. We have chosen to start the journey to gene therapy with one of the most severe, the G11778A mutation in mtDNA responsible for LHON, a disease renowned for causing blindness in later childhood and early adulthood.3 It shows little or no propensity for recovery and there is no effective therapy for this or any disease caused by mutated mtDNA.4

This publication has 24 references indexed in Scilit: